Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Ironwood Pharmaceuticals, Inc. (IRWD) vs Pacira BioSciences, Inc. (PCRX)

Ironwood Pharmaceuticals, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Pacira BioSciences, Inc. is the larger, with a market value of $1.0B against $692.4M — 1.5× the size. Ironwood Pharmaceuticals, Inc. trades at the lower P/E: 5.2× against 71.8×. Ironwood Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 26.2% against 5.71%. Ironwood Pharmaceuticals, Inc. has the higher net margin (33.4% vs 1.96%) and the higher return on invested capital (101.6% vs 1.58%). Across the 21 metrics below, Ironwood Pharmaceuticals, Inc. leads on 16 and Pacira BioSciences, Inc. on 5.

Valuation

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
P/E 5.18 71.77 20.14
P/S 1.74 1.33 2.25
P/B n/m 1.48 1.90
Price to free cash flow 3.66 5.52 16.54
EV/EBITDA 5.02 12.68 12.29
EV/Sales 3.04 1.75 2.56
Earnings yield 19.31% 1.39% (2.99%)
Free cash flow yield 27.32% 18.11% 0.00%

Profitability

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 79.21% 53.94%
Operating margin 60.15% 2.66% 0.00%
Net margin 33.36% 1.96% 0.00%
Free cash flow margin 47.66% 24.06% 0.00%
Return on equity (55.26%) 2.05% (0.40%)
Return on assets 41.35% 1.05% (3.32%)
Return on invested capital 101.61% 1.58% 0.00%

Growth

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 26.19% 5.71% 10.01%
EPS growth (last fiscal year) 2,627.27% 107.44% —
Revenue growth, 5-year CAGR (5.33%) 11.07% 6.74%
Net income growth, 5-year CAGR (25.72%) (45.44%) 0.00%

Health

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
Debt to equity (2.38) 0.54 0.05
Current ratio 6.06 5.04 2.31
Net debt to EBITDA 3.68 1.24 0.85

Dividend

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric IRWD PCRX Drug Manufacturers Specialty & Generic median
Market cap 692.36m 1.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack